Related Experiment Video
Updated: Dec 21, 2025

Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Optimizing Medication Treatment of Opioid Use Disorder During COVID-19 (SARS-CoV-2)
Idris E Leppla1, Marielle S Gross
1Department of Psychiatry, Johns Hopkins School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD (IEL); Johns Hopkins Bloomberg School of Public Health, The Johns Hopkins Berman Institute of Bioethics, Baltimore, MD (MSG).
Abstract:
: The COVID-19 health crisis joined, rather than supplanted, the opioid crisis as the most acutely pressing threats to US public health. In the setting of COVID-19, opioid use disorder treatment paradigms are being disrupted, including the fact that methadone clinics are scrambling to give "take-home" doses where they would typically not. The rapid transition away from in-person examination, dosing and group therapy in an era of social isolation calls for adjustments to clinical practice, including emphasizing patient-provider communication, favoring new inductees on buprenorphine and leveraging technology to optimize safety of medication treatment.
More Related Videos
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
09:54Combining Laser Capture Microdissection and Microfluidic qPCR to Analyze Transcriptional Profiles of Single Cells: A Systems Biology Approach to Opioid Dependence
Published on: March 8, 2020
Related Concept Videos
Drug Therapy
Antianxiety Medications
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Opioid Analgesics: Morphine and Other Natural Cogeners
Analgesia and Pain Management
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment